Summary
GlobalData's clinical trial report, “Lennox-Gastaut Syndrome Global Clinical Trials Review, H1, 2016" provides an overview of Lennox-Gastaut Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Lennox-Gastaut Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.
The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Reasons to buy
- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level
*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Companies Mentioned
The Lundbeck Foundation
Eisai Co., Ltd.
GW Pharmaceuticals Plc
GlaxoSmithKline Plc
Johnson & Johnson
SymPhar Sp. z.o.o.
ProductLife Group SA
Mylan N.V.
Lotus Labs Pvt. Ltd.
INSYS Therapeutics, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Report Guidance 4
Clinical Trials by Region 5
Clinical Trials and Average Enrollment by Country 6
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Clinical Trials by G7 Countries: Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials 13
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials 17
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Lennox-Gastaut Syndrome Therapeutics Clinical Trials 28
Prominent Drugs 30
Clinical Trial Profile Snapshots 31
Appendix 64
Abbreviations 64
Definitions 64
Research Methodology 65
Secondary Research 65
About GlobalData 66
Contact Us 66
Disclaimer 66
Source 67
List of Tables
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Region, 2016* 5
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 14
Lennox-Gastaut Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Lennox-Gastaut Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 18
Lennox-Gastaut Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Lennox-Gastaut Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 27
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 29
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
List of Figures
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2016* 5
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 6
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials, G7 Countries (%), 2016* 13
Lennox-Gastaut Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Lennox-Gastaut Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Lennox-Gastaut Syndrome to Central Nervous System Clinical Trials, E7 Countries (%), 2016* 17
Lennox-Gastaut Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Lennox-Gastaut Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Lennox-Gastaut Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Lennox-Gastaut Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 30
GlobalData Methodology 65
